On February 1, Merck announced its 2018 results, bringing revenue to 422.$9.4 billion, a 5% increase, of which pharmaceutical revenue was 376. 5%.$8.9 billion (+ 6%), Animal Health Business 42.$1.2 billion (+ 9%).The total R & D investment of Merck in 2018 is 97.$5.2 billion, as a share of revenue 23.1%, down 6% from 2017.
The most concerned product of Merck is Keytruda.After four years of struggling, Keytruda has staged a stunning 71.71 dollars.In particular, the 88% year-round increase disfigured Opdivo (+ 36%).Both Opdivo and Keytruda will be on the top 10 global drug rankings this year, and by this trend, Opdivo will have sales of more than $10 billion in 2019.
Another star product from Merck is the cervical cancer vaccine Gardasil 9.Gardasil 9 has emerged in China as the release of huge demand from the Chinese market.Gardasil 9's 2018 growth is only 37%, and sales are up 31.$5.1 billion.
$600 million fell directly to 4.For $5.5 billion, it also gave Merck a taste of the elevator.The other is Remicade, which is plagued by biological analogues, and has only 5.$8.2 billion, down 31%.
Merck and AstraZeneca reached a cooperative development alliance for the PARP inhibitor olaparib, and Eisai reached a cooperative development alliance for envatinib, which was also obtained from these two drugs respectively in 2018.87 and $149 million in coalition revenue.